A major Australian drug company is introducing a new class of drugs to treat atrial and ventricular fibrillations, which is a condition caused by a blocked artery.
The drugs target a protein in the body called Myoglobin.
The protein helps to prevent clots from forming in the blood vessels.
Atrial f, which can be caused by heart attacks, is also known as atrial atrioventricular disorder.
The new drug, a generic, has been approved in Europe and the United States.
It is the first of a new generation of drugs targeted at this condition.
At the moment, there are only two drugs approved for atrial disease in the US and Australia, and they are both based on a single molecule.
This drug, called atrial plasminogen activator inhibitor-1 (AT-1), is also the first drug to target a single protein.
The researchers say they are confident it will be effective.
The drug will be marketed under the trade name Atrial Propecia, and the first phase of clinical trials will begin in the first quarter of next year.
The team from the University of Queensland in Brisbane says the drug targets a protein called MyHg, which they call Myoglobin-B2, which binds to the Myoglobin protein in cells and inhibits it.
The peptide has been previously used in other drugs to block atrial flow, but the new drug targets the MyHgs directly, the researchers say.
They are optimistic that the drug will also work in other tissues.
The first clinical trials are expected to begin next year, and researchers expect to see the drug in clinical trials in two years.
The research is being done by the Australian company Biogen Idec, which makes the Atrial plasmid.
A spokesperson said the company had invested in a group of Australian scientists who were working on the drug.
“We are very proud of the work of the researchers, and are confident that the Atriovirals drug will make a significant impact in the future,” the spokesperson said.
Dr David Smith, an associate professor of pharmacology at the University at Adelaide, said there were already a number of drugs in the pipeline for atriospinal disorders.
“But they are really very small molecules,” he said.
Dr Smith said the drug was the first such drug approved in Australia, but other drugs in development could also be in clinical testing. “
The drug does not bind to the heart’s endothelium or other tissues that are involved in myocardial infarction, so the drugs are not really targeting the heart.”
Dr Smith said the drug was the first such drug approved in Australia, but other drugs in development could also be in clinical testing.
The company is also working on a drug that targets a different protein, called MyHC2, the team said.
They were hoping the drug could be used in people who have had heart attacks and are still not responding to conventional treatment.
The Australian team hopes the drug would be able to be given to people in their early thirties or for people with existing heart problems.
It could be available within five years.
Dr Smith described the drug as a breakthrough, saying the team hoped to have the drug available in five years’ time.
He said it could be more effective than existing treatments.
The Atriostis team is now working on several other drugs for atria, but Dr Smith told ABC Radio National the Atria team had already been developing atrial drugs.
“It is just about the development of the other drugs,” he added.
He says there were a number companies who had developed drugs, but he said there was “never any indication that there was a large market”.
He said a major problem was the drug companies not being able to compete with generic drugs.